We help oncology laboratory pharma professionals enhance patient care
Oncology professionals
We ensure NGS testing is simple to organise with timely results provided in a timely way signposting you to treatment choices that will benefit your patients.
Laboratory professionals
Our solutions always ensure that NGS testing and its clinical interpretation is delivered in a timely way for the benefit of patients.
Pharma professionals
We can gather the information needed to precisely match patients to drugs, evidencing clinical efficacy, safety and patient benefit.
Years of trust, countless tests run, genes, and trials explored
Our mission
OncoDNA’s ultimate mission is to improve all patients’ health by empowering healthcare providers, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.
Every day, our dedicated efforts focus on enhancing patient
access to Precision Medicine
MGI and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practice
Gosselies – Belgium, October 29, 2024 MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced...
The NHS South East Genomic Medicine Service transitions to the OncoDEEP Kit a Solid Tumour Panel that can transform oncology patients’ lives as a result of timely comprehensive genomic testing.
The NHS South East Genomic Medicine Service serves approximately 15.4% of the population of England and seeks to improve patient outcomes through care pathway development enabling timely and equitable access to genomic testing and genomically...
Validation of the OncoDEEP® Kit comprehensive genomic panel on the MGI platform
Introduction : This study aims to compare tumour characterization using the OncoDEEP® Kit end-to-end solution with an MGI sequencer as an alternative to Illumina technology. The validation results demonstrate that the MGI platform, by generating...
OncoDNA to attend the 36th European Congress of Pathology (ECP) in Florence
OncoDNA is taking part in the 36th European Congress of Pathology (ECP), to be held from 7 to 11 September 2024 in Florence, Italy. This event brings together pathology experts from across Europe to discuss...
Analytical validation of HRD calculation performed with the OncoDEEP® Kit Comprehensive Genomic Panel
Introduction : HRD validation with OncoDEEP® Kit for ovarian cancer This poster highlights the results of a rigorous study conducted on 76 ovarian carcinoma samples from four Spanish hospitals. The OncoDEEP® kit stands out for...
Detection of Intraspecies Contamination as a Quality Control Tool in The OncoDEEP® Kit Comprehensive Genomic Panel
Introduction Next-Generation sequencing (NGS) emerged as a revolutionary technology in genomics research aiding precision medicine for almost two decades, but it has its challenges. One of which is the intraspecies contamination which could affect assay’s...
Dr. Ofer Elhanani I’m a staff scientist in Dr. Leeat Keren’s lab at the Weizmann Institute of Science in Israel. In our lab, we focus on research questions related to the interactions between tumor cells...
Scientific Review: latest discoveries in precision oncology
In a rapidly evolving medical landscape, staying updated with the latest breakthroughs is crucial. Our team of experts constantly monitors the field to bring you the most relevant and groundbreaking news. This month, we’ve handpicked...
Discover the latest version of our OncoKDM™ analysis software. In addition to delivering a comprehensive interpretation report, our platform now provides an even deeper analysis of QC data, empowering your laboratory with the precision necessary for accurate insights....
